CClinicalTrials.gg
Not yet recruitingNCT07733596Updated Jul 29, 2026

Development of a Digital Acceptance and Commitment Therapy Intervention for Suicide Prevention in Adults Through Co-design

An interventional study of Digital ACT Intervention in Suicide, Co-design and Suicide Prevention, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Suicide is a major public health concern and there is a need for accessible and scalable interventions to support individuals experiencing suicidal thoughts. The aim of this study is to develop a digital Acceptance and Commitment Therapy (ACT) intervention for suicide prevention in Chinese adults through co-design. The study will involve literature review, interviews, and co-design activities to identify user needs, preferences, and contextual factors, and to develop the intervention. Following intervention development, a pilot study will be conducted to evaluate the feasibility, usability, acceptability, and user engagement of the intervention. Findings from this study will inform further refinement of the intervention and future evaluation studies.

02

Conditions studied

  • Suicide
  • Co-design
  • Suicide Prevention
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18 years or older;

    1. Have experienced suicidal thoughts and/or behaviors;
    2. Able to read and communicate in Chinese; Professionals

    <!-- -->

    1. Aged 18 years or older;
    2. Professionals with experience relevant to suicide prevention, Acceptance and Commitment Therapy (ACT), digital mental health, or related fields;

Exclusion criteria

  1. Unable to provide informed consent or participate in study activities;

    1. Currently experiencing acute suicide risk requiring immediate intervention;
    2. Severe cognitive impairment or active psychotic symptoms that would prevent participation.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Digital ACT Intervention

    The Digital ACT Intervention will be co-designed with stakeholders and informed by co-design activities. The intervention aims to support adults experiencing suicidal thoughts through a digital platform.

    Behavioral: Digital ACT Intervention

Interventions

  • BehavioralDigital ACT Intervention

    A co-designed digital Acceptance and Commitment Therapy (ACT) intervention for suicide prevention

05

What researchers measure

Primary outcomes

  1. Intervention completion rate

    The intervention completion rate will be assessed as the percentage of participants who complete the digital intervention, based on intervention usage records.

    Time frame: End of the intervention (approximately 2 weeks)

  2. Retention rate

    The participant retention rate will be assessed as the percentage of participants who complete the post-intervention assessment and the follow-up assessment.

    Time frame: End of the 1-month follow-up

  3. Acceptability outcome

    Acceptability of the intervention will be assessed using participant-reported ratings and feedback regarding satisfaction and overall experience with the intervention.

    Time frame: End of the intervention (approximately 2 weeks)

  4. Usability outcome

    Usability will be assessed using the System Usability Scale (SUS), a 10-item self-report questionnaire. Total scores range from 0 to 100, with higher scores indicating better usability of the intervention.

    Time frame: End of the intervention (approximately 2 weeks)

Secondary outcomes

  1. Suicide ideation

    Suicidal ideation will be assessed using the Beck Scale for Suicide Ideation (BSSI). Each item is rated on a 3-point scale ranging from 0 to 2, with higher scores indicating greater suicidal ideation.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  2. Psychological flexibility and inflexibility

    Psychological flexibility and inflexibility will be assessed using the Multidimensional Psychological Flexibility Inventory-24 (MPFI-24). Each item is rated on a 6-point scale ranging from 1 to 6. Higher scores on the flexibility and inflexibility subscales indicate greater psychological flexibility and psychological inflexibility, respectively.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  3. Psychological Distress

    Psychological distress will be assessed using the Depression Anxiety Stress Scales (DASS). Each item is rated on a 4-point scale ranging from 0 to 3, with higher scores indicating greater psychological distress.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  4. Mental well-being

    Mental well-being will be assessed using the Mental Health Continuum-Short Form (MHC-SF). Each item is rated on a 6-point scale ranging from 0 to 5, with higher scores indicating greater mental well-being.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

Other outcomes

  1. Qualitative Feedback and Design Recommendations

    Qualitative feedback related to user needs, preferences, barriers, facilitators, cultural considerations, and recommendations for intervention refinement will be identified from co-design activities and feedback sessions.

    Time frame: Through study completion, an average of 6 months

  2. Cultural Relevance

    Cultural relevance of the intervention will be assessed through participant feedback regarding the appropriateness, relevance, and cultural fit of the intervention content and delivery.

    Time frame: Through study completion, an average of 6 months

06

Study locations

1 site
  • The Hong Kong Polytechnic University
    Hong Kong, China
    • Bryant Hui · Contact · +85227667744
07

Registry details

Key details

Study ID
NCT07733596
Lead sponsor
The Hong Kong Polytechnic University
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Tao Zhang
Contact
tao-t.zhang@connect.polyu.hk
+85294233827
Tao Zhang
principal investigator · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion